India braces for weight-loss drug boom as Ozempic patent expires

India is on the cusp of a significant transformation in its weight-loss and diabetes treatment landscape with the impending expiry of Novo Nordisk's patent for semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, on March 20, 2026. This event is set to unleash a wave of generic versions, potentially making these sought-after medications more accessible and affordable for a wider population in India. The market is anticipating a dramatic price reduction, with estimates suggesting a drop of 50-80% compared to the current innovator brand prices. This could bring the monthly cost of semaglutide injectables down from the current range of ₹8,800-₹16,400 to an estimated ₹3,000-₹4,000. At least 50 Indian pharmaceutical companies, including major players like Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Mankind Pharma, Cipla, and Lupin, are gearing up to launch their generic semaglutide brands on or shortly after the patent expiry. Companies are also innovating in drug delivery systems, with Zydus Lifesciences planning to launch a reusable multi-dose pen. The entry of these generics is expected to fuel a significant boom in the GLP-1 market in India, which is projected to grow substantially in the coming years. CareEdge Ratings estimates the Indian GLP-1 drug market could expand from approximately ₹10 billion in 2025 to as much as ₹50 billion by 2030. Semaglutide, a GLP-1 receptor agonist, mimics a natural gut hormone to help regulate blood sugar and reduce appetite, leading to significant weight loss. While initially approved for Type 2 diabetes, its effectiveness in weight management led to its off-label use and eventually the development of a higher-dose version, Wegovy, specifically for obesity. The drug's popularity has surged globally and in India, driven by its efficacy and increasing awareness of obesity as a major health concern. India has a large population grappling with obesity and diabetes, with over 254 million people living with obesity and over 100 million adults with diabetes. However, the impending boom is accompanied by significant concerns regarding the misuse and off-label promotion of these powerful drugs. The Indian drug regulator, CDSCO, has issued advisories to curb exaggerated claims and prevent brand recall through disease awareness campaigns. The Indian Medical Association (IMA) has also raised alarms about potential misuse and mis-prescription, advocating for stricter controls and limiting prescriptions to certified endocrinologists or diabetologists. The rapid availability of these drugs and the potential for inadequate verification of prescriptions are fueling these concerns. To address these issues, India's drug regulator has banned all advertisements for GLP-1 drugs, aiming to curb misuse and prevent misleading promotions. While Novo Nordisk, the originator of Ozempic and Wegovy, will see its patent expire in India, the company states it is driven by patient trust, not patents, and is not dropping its prices despite competition. In contrast, Eli Lilly's tirzepatide drug Mounjaro, which mimics an additional hormone (GIP), has a patent until 2035 and currently holds a significant share of the Indian weight-loss market. Mounjaro has seen remarkable success in India, becoming the top-selling drug by value in October 2025, indicating a strong demand for advanced weight-loss therapies. The competition between Lilly and Novo Nordisk has made India a key battleground for these global pharmaceutical players. The expiry of semaglutide's patent in India is a landmark event, poised to democratize access to advanced weight-loss treatments. The influx of generics promises to bring down prices significantly, making these therapies available to a much larger segment of the Indian population. However, the success of this transition hinges on robust regulatory oversight, responsible marketing practices, and increased awareness among both healthcare providers and consumers to ensure safe and effective use, thereby mitigating the risks of misuse and adverse effects.

Frequently Asked Questions

Read Full Story on Quick Digest